FTC V. Actavis: Reconciling Conflicts In Rule Of Reason
July 2, 2013, 5:55 PM EDT
Law360, New York (July 2, 2013, 5:55 PM EDT) -- The U.S. Supreme Court’s June 17 decision in Federal Trade Commission v. Actavis has already spawned a cascade of commentary. Its core holding has big implications for the pharmaceutical industry: The court concluded that lower courts were wrong to dismiss the FTC’s complaint challenging a “reverse payment” agreement where the patent-holder allegedly paid generic drug companies, the putative infringers, to delay their generic entry.
But contained in the final section of the court’s decision is a discussion of "rule of reason" that stretches beyond one industry...
Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.